QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV

15-Oct-2010 - QIAGEN and Abbott announced that they have entered into an agreement that significantly strengthens both companies’ testing menus for automated in-vitro diagnostic applications in the United States and Canada. Financial terms were not disclosed. Under the terms of the agreements, QIAGEN will ...

Zetiq Technologies and Biomics Biotechnologies Sign Collaboration Agreement

Collaboration agreement for the development and commercialization of screening and diagnosis technology of cervical cancer

28-Apr-2010 - Bio-Light announces the signing of a collaboration agreement between its subsidiary, Zetiq Technologies, and the Chinese company, Biomics Biotechnologies, whose expertise lies in the development and sales of medical and diagnostic products. This follows a memorandum of understanding signed ...

ITT agrees to purchase Nova Analytics

29-Mar-2010 - ITT Corporation announced its agreement to purchase Nova Analytics Corporation. Nova Analytics is a privately held manufacturer of premium quality laboratory, field, portable, and on-line analytical instruments used in water and wastewater, environmental, medical, and food and beverage ...

Thermo Fisher Scientific Signs Agreement to Acquire Leading Innovator in Handheld Spectrometers, Ahura Scientific

21-Jan-2010 - Thermo Fisher Scientific Inc. announced that it has signed a definitive agreement to acquire Ahura Scientific for $145 million in cash plus the potential for an earn-out payment based on the achievement of certain 2010 financial targets. Ahura Scientific's products expand Thermo Fisher's ...

QIAGEN Acquires ESE GmbH

14-Jan-2010 - QIAGEN N.V. announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash. ESE has pioneered the development and manufacturing of ...

Spectral Diagnostics enters into strategic collaboration with BioMS Medical to commercialize treatment for sepsis

21-Dec-2009 - Spectral Diagnostics Inc. and BioMS Medical Corp. announced that BioMS Medical and a syndicate of investors have invested $14 million in Spectral Diagnostics to advance Toraymyxin(TM), a treatment for severe sepsis, towards regulatory approval and commercialization in the United ...

Varian, Inc. Announces Stockholder Approval of Merger Agreement With Agilent Technologies

09-Oct-2009 - Varian, Inc. announced that at a special meeting of stockholders held on October 5, 2009, its stockholders adopted the merger agreement entered into with Agilent Technologies, Inc., under which Agilent will acquire Varian for $52.00 per share in cash. Approximately 84% of the shares of Varian ...

Successful sale of BRAHMS in an all cash transaction to Thermo Fisher

Scientific leads to NAV increase of CHF 8.88, or 15.5%

04-Sep-2009 - Thermo Fisher Scientific Inc. and BRAHMS Holding GmbH announced the signing of a definitive Share Purchase Agreement. Under the terms of the agreement Thermo Fisher Scientific will acquire all issued shares of BRAHMS for a gross purchase price of EUR 330 million (approximately USD 470 million), ...

Agilent Technologies to Acquire Varian, Inc. for $1.5 Billion

03-Aug-2009 - Agilent Technologies Inc. and Varian, Inc. announced that they have signed a definitive agreement for the acquisition by Agilent of Varian. Agilent will pay $52 cash per share of common stock for Varian in a transaction that represents a premium of approximately 35% to Varian’s closing price on ...

QIAGEN Tests Clinically Verified for the Monitoring of Swine Flu

German Bernhard Nocht Institute Unequivocally Detects Infections with the H1N1 Strain Using the artus Influenza Test

07-May-2009 - Analyses performed by the German Bernhard Nocht Institute for Tropical Medicine have proven that the influenza A / H1N1 virus can be unequivocally detected using a screening test developed by QIAGEN. The company's artus Influenza LC RT PCR Kit was successfully used to screen a female patient who ...